---
title: "Incyte Corp. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293386527.md"
description: "Incyte Corp. (INCY) shares rose 1.50% to $117.39, outperforming competitors like Alnylam and Bio-Techne during a strong market session where the S&P 500 and Dow Jones also gained. Trading volume exceeded its 50-day average, and the stock closed just below its 52-week high of $119.60."
datetime: "2026-07-21T21:03:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293386527.md)
  - [en](https://longbridge.com/en/news/293386527.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293386527.md)
---

# Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. (INCY) advanced 1.50% to $117.39 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.89% to 7,509.20 and the Dow Jones Industrial Average rising 0.74% to 52,224.64.

Incyte Corp. closed 1.85% short of its 52-week high of $119.60, which the company reached on July 17th.

The stock outperformed some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. (ALNY) fell 0.48% to $271.37, Bio-Techne Corp. (TECH) fell 0.01% to $71.63, and BioMarin Pharmaceutical Inc. (BMRN) rose 0.17% to $59.21.

Trading volume (1.9 M) eclipsed its 50-day average volume of 1.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 21, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-21-26 1703ET

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [INCY: Q2 2026 revenue grew 38% year-over-year, driven by strong sales and a one-time Opzelura benefit](https://longbridge.com/en/news/294056998.md)
- [Incyte Says It's No Longer A One-Drug Story](https://longbridge.com/en/news/294105383.md)
- [Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results](https://longbridge.com/en/news/294226716.md)
- [Incyte expects Opzelura to cross $1B in 2026](https://longbridge.com/en/news/294223769.md)
- [What To Expect From Incyte’s (INCY) Q2 Earnings](https://longbridge.com/en/news/293873820.md)